GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/LLMs Improve Accuracy and Completeness of Cancer Pathology Summaries | JCO Clinical Cancer Informatics
69

LLMs Improve Accuracy and Completeness of Cancer Pathology Summaries | JCO Clinical Cancer Informatics

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated April 1, 2026

Introduction

Modern oncology care depends on rapid interpretation of increasingly complex pathology reports that integrate histopathology, immunohistochemistry and molecular profiling. Synthesizing these data into concise, clinically usable summaries is time-intensive and cognitively demanding, creating workflow burden and increasing the risk of omission in busy oncology practice.

Problem Statement

Conventional physician-authored pathology summaries are often efficient but may incompletely capture key diagnostic and genomic information, particularly as molecular testing becomes more complex and voluminous. Large language models (LLMs) offer a potential solution, but their clinical reliability, completeness and safety in summarizing oncology pathology reports require careful evaluation before integration into routine practice.

Summary

This study demonstrates that open-source LLMs can generate clinically useful summaries of complex cancer pathology reports with greater completeness than physician-authored summaries while maintaining comparable correctness. Across 94 thoracic oncology cases, most LLMs outperformed physician summaries on objective measures of fidelity and consistently captured more complete clinicopathologic and genomic information, particularly molecular findings that were frequently omitted in routine documentation. Importantly, top-performing models maintained strong factual accuracy and low rates of clinically meaningful error, suggesting that LLM-assisted summarization can reduce documentation burden without compromising clinical usability. Performance, however, was model dependent: newer systems such as DeepSeek and Llama 3.1/3.2 performed reliably, whereas older or shorter-context models were more prone to omissions, unusable outputs and clinically relevant errors. The study highlights a key practical advantage of LLMs in oncology workflows—the ability to standardize and scale synthesis of increasingly complex pathology and genomic data—while also emphasizing the need for model selection, human oversight and task-specific validation. These findings support LLM-assisted pathology summarization as a promising workflow tool to improve documentation efficiency, reduce cognitive burden and enhance clinical information accessibility in cancer care.

Related Q&A

70

Raltitrexed Shows Limited Clinical Activity in Advanced Colorectal Cancer | The Oncologist

Introduction Thymidylate synthase inhibition remains a central therapeutic strategy in colorectal cancer, most commonly achieved with fluoropyrimidines such as 5-fluorouracil (5-FU). Raltitrexed, a direct thymidylate synthase inhibitor, was...

71

Dual NAMPT–KRAS Targeting Emerges as a Promising Strategy in PDAC | CancerNetwork

Introduction KRAS remains the dominant oncogenic driver in pancreatic ductal adenocarcinoma (PDAC), yet therapeutic targeting of KRAS has produced only modest and often short-lived responses due to rapid...

72

RFA Fails to Improve Outcomes in Locally Advanced Pancreatic Cancer | JAMA Network Open

Introduction Locally advanced pancreatic cancer (LAPC) remains a highly lethal disease with limited therapeutic options and poor long-term survival. For patients who remain unresectable after induction chemotherapy, local...

73

Early-Onset Disease Is Reshaping the Global Burden of Colorectal Cancer | Nature Reviews Clinical Oncology

Introduction Colorectal cancer (CRC) remains the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality worldwide. Although CRC has historically been concentrated in Western...

74

Temab-A in Refractory Colorectal Cancer: JCO | May 2026

Introduction Treatment options for metastatic colorectal cancer (mCRC) in late-line settings remain limited, particularly in patients with microsatellite stable disease. Antibody-drug conjugates (ADCs) targeting tumour-specific pathways represent an...

75

Biology-Driven Scoring Is Redefining Risk Stratification in Colorectal Liver Metastases: ESMO Open

Introduction Colorectal liver metastases (CRLM) remain a major determinant of mortality in colorectal cancer, with hepatic resection offering the best chance of long-term survival in selected patients. However,...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer